A Phase 3 interventional study of Apixaban and Placebo in Acute Coronary Syndrome, sponsored by Bristol-Myers Squibb. Terminated at 1,014 sites in 40 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-27.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.
Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 19th largest by enrollment of the 186 interventional ones that give a count, is one of 15 that started in 2009, is one of 40 in phase 3, and was the 55th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
Columbia University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of South Florida · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 36 · Phase 3 41 · Phase 4 27
First in 2001; this study’s year is marked. 15 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7,484 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 150 across the 186 interventional studies, 500 across the 79 observational. Of the 214 that completed or were terminated, 97 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 265 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 4 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Coronary Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05918861Phase 3DalCor PharmaceuticalsEffect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | 2027-08 |
| NCT06481943SB Technology, Inc.A Prospective Research Investigation of Ischemia Using MCG | 2026-12 |
| NCT05412927Angel Medical SystemsAngelMed Guardian® System PMA Post Approval Study | 2026-12 |
| NCT04496687SCAD AllianceInternational Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | 2026-12-31 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 265 studies in Acute Coronary Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Apixaban
Drug: Placebo
Tablets, Oral, 5 mg, twice daily, until study end
Also known as: BSM-562247
Tablets, Oral, 0 mg, twice daily, until study end
Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants
Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).
Time frame: Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years
Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants
TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days.
Time frame: From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants
Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).
Time frame: Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years
Event Rate of Stroke During the Intended Treatment Period - Randomized Participants
Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination).
Time frame: Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years
Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants
MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3\*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5\*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice.
Time frame: Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years
Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants
Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination.
Time frame: Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years
Event Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants
Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).
Time frame: Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years
Event Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants
Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).
Time frame: Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years
Event Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants
Cause of death was determined by the principal condition that caused the death, not the immediate mode of death. CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).
Time frame: Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years
Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants
ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days.
Time frame: From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants
ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days.
Time frame: From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants
Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days.
Time frame: From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Milestone | Placebo BID | Apixaban 5 mg BID |
|---|---|---|
| Started | 3687 | 3705 |
| Treated | 3643 | 3672 |
| Completed | 0 | 0 |
| Not completed | 3687 | 3705 |
| Withdrew: Death | 82 | 81 |
| Withdrew: Adverse event | 248 | 321 |
| Withdrew: Emergency procedure | 2 | 2 |
| Withdrew: Elective procedure | 26 | 25 |
| Withdrew: Physician decision | 26 | 35 |
| Withdrew: No longer met criteria | 13 | 19 |
| Withdrew: Withdrawal by subject | 178 | 212 |
| Withdrew: Lost to follow-up | 26 | 35 |
| Withdrew: Administrative reason by sponsor | 2780 | 2671 |
| Withdrew: Poor/non-compliance | 30 | 38 |
| Withdrew: Non-specified | 276 | 266 |
| Milestone | Placebo BID | Apixaban 5 mg BID |
|---|---|---|
| Started | 3508 | 3529 |
| Completed | 3375 | 3355 |
| Not completed | 133 | 174 |
| Withdrew: Withdrawal by subject | 41 | 34 |
| Withdrew: Lost to follow-up | 13 | 27 |
| Withdrew: Death | 63 | 86 |
| Withdrew: Non-specified | 16 | 26 |
| Withdrew: Missing end of study status | 0 | 1 |
Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants | 13.96 | 13.20 |
Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants | 4.21 | 3.95 |
Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination).
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Stroke During the Intended Treatment Period - Randomized Participants | 1.85 | 1.65 |
MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3\*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5\*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice.
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants | 9.20 | 8.59 |
Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination.
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants | 2.21 | 1.61 |
Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants | 17.95 | 16.92 |
Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants | 14.27 | 13.97 |
Cause of death was determined by the principal condition that caused the death, not the immediate mode of death. CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants | 15.65 | 15.48 |
TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days.
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants | 0.91 | 2.40 |
ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days.
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants | 2.04 | 5.13 |
ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days.
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants | 2.29 | 6.15 |
Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days.
| percentage of participants/100-pt years | Placebo | Apixaban 5 mg BID |
|---|---|---|
| Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants | 16.33 | 39.98 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban 5 mg BID | — | 894/3,672 (24.3%) | 357/3,672 (9.7%) |
| Placebo BID | — | 884/3,643 (24.3%) | 231/3,643 (6.3%) |
| Event | Apixaban 5 mg BID | Placebo BID |
|---|---|---|
| Myocardial infarctionCardiac disorders | 150/3672 | 158/3643 |
| Angina unstableCardiac disorders | 157/3672 | 157/3643 |
| Cardiac failureCardiac disorders | 94/3672 | 82/3643 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 69/3672 | 23/3643 |
| Non-cardiac chest painGeneral disorders | 38/3672 | 46/3643 |
| Angina pectorisCardiac disorders | 37/3672 | 41/3643 |
| Cerebrovascular accidentNervous system disorders | 20/3672 | 39/3643 |
| PneumoniaInfections and infestations | 35/3672 | 35/3643 |
| Atrial fibrillationCardiac disorders | 26/3672 | 29/3643 |
| Coronary artery diseaseCardiac disorders | 22/3672 | 18/3643 |
| Event | Apixaban 5 mg BID | Placebo BID |
|---|---|---|
| Chest painGeneral disorders | 186/3672 | 173/3643 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 186/3672 | 63/3643 |
Randomized participants
| Age, Continuous(years) | Placebo | Apixaban 5 mg BID | Total |
|---|---|---|---|
| Mean | 65.4 ± 11.05 | 65.3 ± 10.89 | 65.4 ± 10.97 |
| Age, Customized(participants) | Placebo | Apixaban 5 mg BID | Total |
|---|---|---|---|
| < 65 years | 1512 | 1526 | 3038 |
| ≥ 65 and < 75 years | 1420 | 1440 | 2860 |
| ≥ 75 years | 755 | 739 | 1494 |
| Sex: Female, Male(Participants) | Placebo | Apixaban 5 mg BID | Total |
|---|---|---|---|
| Female | 1169 | 1209 | 2378 |
| Male | 2518 | 2496 | 5014 |
| Region of Enrollment(participants) | Placebo | Apixaban 5 mg BID | Total |
|---|---|---|---|
| Russian Federation | 540 | 542 | 1082 |
| Puerto Rico | 13 | 17 | 30 |
| Singapore | 11 | 14 | 25 |
| United States | 450 | 455 | 905 |
| Austria | 58 | 56 | 114 |
| Sweden | 50 | 55 | 105 |
| Netherlands | 45 | 52 | 97 |
| China | 36 | 39 | 75 |
| Poland | 176 | 177 | 353 |
| Korea, Republic of | 88 | 89 | 177 |
| Brazil | 125 | 125 | 250 |
| Slovakia | 30 | 29 | 59 |
| France | 22 | 18 | 40 |
| Bulgaria | 100 | 102 | 202 |
| Chile | 30 | 26 | 56 |
| Colombia | 45 | 43 | 88 |
| Argentina | 131 | 125 | 256 |
| Romania | 78 | 80 | 158 |
| Hungary | 121 | 120 | 241 |
| Japan | 91 | 95 | 186 |
| Ukraine | 128 | 130 | 258 |
| United Kingdom | 24 | 21 | 45 |
| Switzerland | 18 | 20 | 38 |
| India | 396 | 398 | 794 |
| Spain | 81 | 79 | 160 |
| New Zealand | 13 | 9 | 22 |
| Canada | 126 | 128 | 254 |
| Czech Republic | 54 | 54 | 108 |
| Turkey | 9 | 11 | 20 |
| Belgium | 47 | 50 | 97 |
| Norway | 26 | 25 | 51 |
| Finland | 4 | 3 | 7 |
| Denmark | 37 | 34 | 71 |
| Italy | 23 | 21 | 44 |
| South Africa | 66 | 67 | 133 |
| Mexico | 161 | 161 | 322 |
| Israel | 73 | 66 | 139 |
| Australia | 15 | 23 | 38 |
| Peru | 66 | 66 | 132 |
| Germany | 80 | 80 | 160 |
| Antiplatelet Therapy(participants) | Placebo | Apixaban 5 mg BID | Total |
|---|---|---|---|
| Dual Antiplatelet Therapy | 2965 | 2968 | 5933 |
| Single Antiplatelet Therapy | 722 | 737 | 1459 |
| ACS Index Event(participants) | Placebo | Apixaban 5 mg BID | Total |
|---|---|---|---|
| STEMI | 1412 | 1426 | 2838 |
| non-STEMI | 1582 | 1581 | 3163 |
| Unstable angina | 693 | 698 | 1391 |
Showing the first 100 of 1,014 sites across 40 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2009, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban